FDA Approves First Liquid, Nonstimulant ADHD Treatment, Onyda XR
By Lori Solomon HealthDay Reporter
MONDAY, June 3, 2024 -- The U.S. Food and Drug Administration has approved once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).
The once-a-day, extended-release, oral suspension treatment is a centrally acting alpha2-adrenergic agonist. It has nighttime dosing for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system stimulant medications in pediatric patients ≥6 years.
Onyda XR is contraindicated in patients with history of a hypersensitivity reaction to clonidine. As monotherapy, the most common adverse reactions (incidence ≥5 percent and twice the rate of placebo) include somnolence, fatigue, irritability, nightmare, insomnia, constipation, and dry mouth. For adjunct therapy, the most common adverse reactions (incidence ≥5 percent and twice the rate of placebo) include somnolence, fatigue, decreased appetite, and dizziness.
"People with ADHD require a range of therapeutic options that are designed for their individual needs, because not every medication or type of therapy works for every patient," Ann Childress, M.D., president of the Center for Psychiatry and Behavioral Medicine in Las Vegas, said in a statement. "The approval of Onyda XR, the only liquid nonstimulant ADHD medication, with nighttime dosing that shifts the release profile, is a convenient option for patients needing better ADHD control."
Approval of Onyda XR was granted to Tris Pharma.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
MONDAY, April 21, 2025 -- Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and...
Exposure to Maternal Cannabis Use Disorder Ups Risk for Youth Behavioral Disorders
MONDAY, March 24, 2025 -- Children exposed to maternal cannabis use disorder (CUD) during pregnancy and postpartum have an increased risk for later behavioral disorders, according...
Western Dietary Pattern During Pregnancy Tied to Child Neurodevelopmental Disorders
WEDNESDAY, March 12, 2025 -- A Western dietary pattern during pregnancy is associated with child neurodevelopmental disorders at age 10 years, particularly...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.